CORDIS - Forschungsergebnisse der EU

Albumin particles for intra-articular delivery of celecoxib to treat osteoarthritic inflammation.


Ein Arzneimittelabgabe-System auf Albuminbasis für Osteoarthritis

Die Behandlung der Autoimmunerkrankung Osteoarthritis (OA) erfolgt vorwiegend symptomatisch, wobei die intraartikuläre (IA) Gabe freier Kortikosteroide und Hyaluronsäure die bestmöglichen Optionen darstellen. Die schnelle Ausscheidung der injizierten Moleküle aus dem Gelenk nach der IA-Verabreichung erfordert jedoch mehrere Injektionen und macht die Behandlung mit diesen Molekülen umständlich und wenig wirksam. Um diese Problematik anzugehen, schlagen die Wissenschaftlerinnen und Wissenschaftler des EU-finanzierten Projekts IA-NANO vor, Albuminpartikel zu entwickeln, die mit dem nicht-steroidalen Entzündungshemmer Celecoxib beladen sind. Dieses lange wirkende Abgabesystem ist biokompatibel und biologisch abbaubar und sollte eine gesteuerte Freisetzung des Medikaments im entzündeten Gelenk ermöglichen, wodurch die Anzahl der Injektionen mit dem freien Medikament reduziert und die Toxizität des Systems vermieden wird.


Osteoarthritis (OA) is the most common chronic condition of the joints and is predicted to become the fourth largest cause of disability in the world by 2020. Its complete mechanism is yet to be deciphered. Though it is not curable, several medications are prescribed to manage the symptomatic OA, of which the oral and topical medications have shortcomings and the better option is the intra-articular (IA) delivery of free corticosteroids and hyaluronic acid. However, IA delivery is challenging due to the rapid clearance of the free injected molecules from the joint space and outcomes are suboptimal in terms of efficacy and a need for repeated injections. Our objective therefore is to load a candidate drug in a long-acting delivery system and inject it directly into the inflamed knee of a rat model of OA, following in vitro bioassay screening in primary human synoviocytes. Thus, in this project, we propose to develop non-toxic, biocompatible and biodegradable albumin particles loaded with the non-steroidal anti-inflammatory cyclooxygenase-2 inhibitor, celecoxib. This method is expected to reduce the side-effects associated with oral administration of celecoxib. In addition, it will also increase the drug local concentration in the joint and the controlled release of the drug will lead to reduction of inflammatory biomarkers in joints. The project is in line with the EU’s Horizon 2020 Programme focus area - Health, Demographic Change and Wellbeing and UN Sustainable Development goal - Good Health and Well-Being. It will be carried out by the researcher and supervisors who are experts in DDSs development, OA therapy and translational pharmaceutics. Both the researcher and the host are expected to benefit in this collaboration and the researcher will gain experience that will increase her future employability. The project will have great societal impact and commercial potential and will also help increase Europe’s position as the leading source of cutting-edge research.


€ 196 590,72
4 Dublin

Auf der Karte ansehen

Ireland Eastern and Midland Dublin
Higher or Secondary Education Establishments
€ 196 590,72